Duodenal Ulcer, Gastric Ulcer
Conditions
Keywords
NSAIDs, Gastric ulcer or duodenal ulcer, Nexium
Brief summary
The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with non-steroidal anti-inflammatory drug (NSAID).
Detailed description
Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with NSAIDs
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
-Patients who are given NSAIDs for long terms to control pain due to disease such as rheumatoid arthritis and osteoarthritis, and given Nexium to suppress recurrence of gastric ulcer or duodenal ulcer.
Exclusion criteria
* Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy) * Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Drug Reactions | 1 Year | Adverse event incidence |
Secondary
| Measure | Time frame |
|---|---|
| Non-recurrence rate of peptic ulcer | 1 Year |
Countries
Japan